VDR and benign prostatic hyperplasia: A few studies based on Asian cohorts as well as patients in western countries indicated that vitamin D receptor polymorphisms are associated with the incidence of prostate cancer, and vitamin D receptor may be a therapeutic target for BPH [12–14].